Atara Biotherapeutics, Inc. (ATRA) is the 66th largest of 117 Gene and Cell Therapy companies by market capitalisation, at 148.00 Mn, behind Z Squared Inc. at 157.24 Mn. The table below compares all 117 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 10.21 Bn | 42.29 | 23.18 | 9.37 Bn |
| 2 | CRSP | CRISPR Therapeutics AG | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 5.04 Bn | -10.42 | 376.41 | 5.04 Bn |
| 3 | IOVA | Iovance Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.65 Bn | -17.48 | 11.24 | 3.36 Bn |
| 4 | LEGN | Legend Biotech Corp | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.54 Bn | -167.93 | 2.78 | 2.57 Bn |
| 5 | QURE | uniQure N.V. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.95 Bn | -14.98 | 157.80 | 2.95 Bn |
| 6 | BEAM | Beam Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.55 Bn | -29.81 | 16.32 | 2.55 Bn |
| 7 | PGEN | Precigen, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.39 Bn | -7.10 | 27.88 | 2.39 Bn |
| 8 | SRPT | Sarepta Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | -15.77 | 1.10 | 1.37 Bn |
| 9 | VCEL | Vericel Corp | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | 77.04 | 6.31 | 1.77 Bn |
| 10 | TSHA | Taysha Gene Therapies, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.91 Bn | -12.76 | 348.19 | 1.91 Bn |
| 11 | NTLA | Intellia Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | -3.98 | 26.74 | 1.59 Bn |
| 12 | SLDB | Solid Biosciences Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.30 Bn | -6.38 | — | 1.30 Bn |
| 13 | MGTX | MeiraGTx Holdings plc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | 7.11 | 2.93 | 1.03 Bn |
| 14 | IMTX | Immatics N.V. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.07 Bn | -4.45 | 22.07 | 0.62 Bn |
| 15 | FDMT | 4D Molecular Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -5.29 | 10.31 | 0.59 Bn |
| 16 | SANA | Sana Biotechnology, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.91 Bn | -4.25 | — | 0.91 Bn |
| 17 | CADL | Candel Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.84 Bn | -12.78 | — | 0.84 Bn |
| 18 | NGNE | Neurogene Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -7.28 | — | 0.81 Bn |
| 19 | IMMX | Immix Biopharma, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -25.62 | — | 0.81 Bn |
| 20 | PRME | Prime Medicine, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -3.16 | 145.98 | 0.59 Bn |
| 21 | ALLO | Allogene Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -3.50 | 125.12 | 0.58 Bn |
| 22 | IRD | Opus Genetics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -5.94 | 58.61 | 0.49 Bn |
| 23 | BNTC | Benitec Biopharma Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -12.18 | — | 0.56 Bn |
| 24 | AUTL | Autolus Therapeutics plc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -2.03 | 4.64 | 0.32 Bn |
| 25 | CAPR | Capricor Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | -3.81 | — | 0.48 Bn |
| 26 | RGNX | REGENXBIO Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -2.55 | 2.39 | 0.35 Bn |
| 27 | KYTX | Kyverna Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -2.93 | — | 0.45 Bn |
| 28 | CABA | Cabaletta Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -2.26 | — | 0.41 Bn |
| 29 | ARTV | Artiva Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -4.53 | — | 0.41 Bn |
| 30 | IPSC | Century Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -3.62 | — | 0.14 Bn |
| 31 | RCKT | Rocket Pharmaceuticals, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.39 Bn | -22.82 | — | 0.39 Bn |
| 32 | LXEO | Lexeo Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.37 Bn | -4.28 | — | 0.37 Bn |
| 33 | OCGN | Ocugen, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -4.24 | 75.80 | 0.25 Bn |
| 34 | PROK | Prokidney Corp. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -2.56 | 418.51 | 0.34 Bn |
| 35 | ABEO | Abeona Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -2.90 | 12.28 | 0.17 Bn |
| 36 | CLLS | Cellectis S.A. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -7.54 | 5.31 | 0.15 Bn |
| 37 | LYEL | Lyell Immunopharma, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -1.16 | 10,557.07 | 0.29 Bn |
| 38 | FATE | Fate Therapeutics Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -2.23 | 43.03 | 0.28 Bn |
| 39 | NWBO | Northwest Biotherapeutics Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -6.97 | 124.71 | 0.27 Bn |
| 40 | LCTX | Lineage Cell Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -10.99 | 19.26 | 0.20 Bn |
| 41 | RNAC | Cartesian Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -2.29 | 168.38 | 0.25 Bn |
| 42 | MEOBF | Mesoblast Ltd | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -4.28 | 2.05 | 0.14 Bn |
| 43 | EDIT | Editas Medicine, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | — | — | 0.09 Bn |
| 44 | TARA | Protara Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -3.30 | — | 0.23 Bn |
| 45 | NKTX | Nkarta, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -1.45 | — | 0.21 Bn |
| 46 | VYGR | Voyager Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -2.34 | 5.58 | 0.08 Bn |
| 47 | DTIL | Precision Biosciences Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -5.49 | 4.14 | 0.10 Bn |
| 48 | ZSQR | Z Squared Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -8.15 | 56.22 | 0.14 Bn |
| 49 | ATRA | Atara Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -6.30 | 23.89 | 0.13 Bn |
| 50 | TNYA | Tenaya Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -1.37 | 105.84 | 0.14 Bn |
| 51 | CRBU | Caribou Biosciences, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -1.24 | 13.59 | 0.02 Bn |
| 52 | HUMA | Humacyte, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -1.12 | 62.93 | 0.13 Bn |
| 53 | ENGN | enGene Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -0.95 | — | 0.12 Bn |
| 54 | ACET | Adicet Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -1.03 | — | -0.02 Bn |
| 55 | ANIX | Anixa Biosciences Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -8.89 | — | 0.09 Bn |
| 56 | INMB | Inmune Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -3.06 | — | 0.04 Bn |
| 57 | INKT | MiNK Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -5.19 | — | 0.06 Bn |
| 58 | APTN | Adaptin Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -10.22 | — | 0.06 Bn |
| 59 | MGX | Metagenomi Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.47 | 2.02 | 0.04 Bn |
| 60 | SGMOQ | Sangamo Therapeutics, Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.35 | 1.08 | 0.02 Bn |
| 61 | TCRX | TScan Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.35 | 5.84 | 0.04 Bn |
| 62 | CELU | Celularity Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.40 | 1.37 | 0.03 Bn |
| 63 | ESLA | Estrella Immunopharma, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.98 | — | 0.03 Bn |
| 64 | TVGN | Tevogen Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.25 | — | 0.03 Bn |
| 65 | MRKR | Marker Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.24 | — | 0.01 Bn |
| 66 | INAB | In8Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.18 | — | 0.02 Bn |
| 67 | LGVN | Longeveron Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.90 | 17.98 | 0.01 Bn |
| 68 | GNTA | Genenta Science S.p.A. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -3.87 | — | 0.02 Bn |
| 69 | PASG | Passage BIO, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.40 | — | 0.02 Bn |
| 70 | BCDA | BioCardia, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.79 | — | 0.01 Bn |
| 71 | ADIA | Adia Nutrition, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -75.51 | 69.62 | 0.01 Bn |
| 72 | PLUR | Pluri Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 | 8.71 | 0.00 Bn |
| 73 | FBLG | FibroBiologics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.65 | — | 0.01 Bn |
| 74 | GDTC | CytoMed Therapeutics Ltd | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -3.25 | 40.49 | 0.01 Bn |
| 75 | SNTI | Senti Biosciences Holdings, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.14 | 552.91 | 0.01 Bn |
| 76 | ZEOX | Zeo ScientifiX, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -2.12 | 1.28 | 0.01 Bn |
| 77 | LNAI | Lunai Bioworks Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.06 | 94.21 | 0.00 Bn |
| 78 | PMCB | PharmaCyte Biotech, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.16 | — | 0.00 Bn |
| 79 | ISCO | International Stem Cell CORP | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -11.15 | 0.37 | 0.00 Bn |
| 80 | MBIO | Mustang Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.15 | — | 0.00 Bn |
| 81 | TPST | Tempest Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.22 | — | 0.00 Bn |
| 82 | CLDI | Calidi Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.07 | — | 0.00 Bn |
| 83 | GNPX | Genprex, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -0.01 Bn |
| 84 | CELZ | Creative Medical Technology Holdings, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.18 | 435.51 | 0.00 Bn |
| 85 | BRTX | BioRestorative Therapies, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.08 | 3.43 | 0.00 Bn |
| 86 | RMTG | Regenerative Medical Technology Group Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.12 | 0.13 | 0.00 Bn |
| 87 | ERNAW | Ernexa Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | 0.00 Bn |
| 88 | JNJ | Johnson & Johnson | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 641.14 Bn | 30.48 | 6.55 | 620.38 Bn |
| 89 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 179.97 Bn | -62.17 | 5.91 | 176.79 Bn |
| 90 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 130.57 Bn | 29.64 | 10.37 | 122.72 Bn |
| 91 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 29.49 Bn | -19.87 | 2,700.12 | 29.49 Bn |
| 92 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.67 Bn | -31.61 | 24.33 | 26.51 Bn |
| 93 | UTHR | UNITED THERAPEUTICS Corp | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 21.47 Bn | 16.38 | 6.81 | 18.80 Bn |
| 94 | NBIX | Neurocrine Biosciences Inc | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.82 Bn | 22.42 | 4.69 | 15.43 Bn |
| 95 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.67 Bn | 173.64 | 3.72 | 11.80 Bn |
| 96 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.10 Bn | -8.16 | 48.86 | 7.74 Bn |
| 97 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.84 Bn | 17.74 | 9.80 | 7.16 Bn |
| 98 | GLPGF | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 99 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.47 Bn | -3.18 | 2.05 | 1.18 Bn |
| 100 | PCRX | Pacira BioSciences, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.00 Bn | 68.31 | 1.34 | 0.75 Bn |
| 101 | NEUP | Neuphoria Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -19.56 | — | 0.44 Bn |
| 102 | AGEN | Agenus Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 3.10 | 2.14 | 0.28 Bn |
| 103 | ALEC | Alector, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -2.71 | 17.13 | 0.06 Bn |
| 104 | CELG-RI | Bristol Myers Squibb Co | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.03 | 0.00 | -10.83 Bn |
| 105 | HURA | TuHURA Biosciences, Inc./NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.22 | — | 0.13 Bn |
| 106 | GUTS | Fractyl Health, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 0.10 Bn | -0.80 | — | 0.10 Bn |
| 107 | PLYX | Polaryx Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -9.77 | — | 0.09 Bn |
| 108 | FBIO | Fortress Biotech, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 9.82 | 1.19 | -0.11 Bn |
| 109 | ATNM | Actinium Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 3.60 | 1.16 | 0.04 Bn |
| 110 | SER | Serina Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.43 | 311.32 | 0.02 Bn |
| 111 | CTXR | Citius Pharmaceuticals, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.33 | 2.14 | 0.02 Bn |
| 112 | ALZN | Alzamend Neuro, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.65 | — | 0.01 Bn |
| 113 | CASIF | CASI Pharmaceuticals, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.02 | 0.12 | 0.00 Bn |
| 114 | BCAB | BioAtla, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.07 | 0.27 | 0.00 Bn |
| 115 | GOVX | GeoVax Labs, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.10 | 2.52 | 0.00 Bn |
| 116 | RNAZ | Transcode Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.04 | — | 0.00 Bn |
| 117 | GRMLW | Greenland Mines Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.02 | — | -0.01 Bn |